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Abstract
I In nt tr ro od du uc ct ti io on n: :   Antibiotic associated diarrhea (AAD) is a frequently encountered
adverse event following antibiotic administration. Evidence suggests that
probiotics may be beneficial in preventing and decreasing the severity of AAD.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Adult patients who were prescribed antibiotics for 3-14
days  were  enrolled  from  eight  Canadian  centers.  Study  treatment  was
randomized at a 1 : 1 ratio of BIO-K+CL1285® or placebo and was administered
within 24 h of initiation to 5 days after termination of antibiotherapy. Patients
were followed for 21 days after last dose of study treatment. The primary
outcome was severity and incidence of AAD. Severity was measured by the total
number of days with diarrhea and incidence was defined as the number of
patients with at least one day with diarrhea over the total number of patients
enrolled in the study.
R Re es su ul lt ts s: :   216 patients were randomized to BIO-K+ and 221 to placebo. The mean
(SD) number of days with diarrhea was 1.19. (3.20) days for the placebo and 0.67
(2.05) days for BIO-K+CL1285® (p = 0.040). Adjusted multivariate linear regression
results showed that the duration of diarrhea for BIO-K+CL1285® vs. placebo 
was reduced by 51.5% (b[SE] = 0.515 [0.256], p = 0.045). The incidence of 
diarrhea  was  21.8%  for  the  BIO-K+  and  29.4%  for  the  placebo  group 
(OR = 0.667, p = 0.067). Multivariate logistic regression, showed that the
adjusted odds ratio of AAD in patients receiving BIO-K+ vs. placebo was 0.627
(p = 0.037). Study treatment was well tolerated. 
C Co on nc cl lu us si io on ns s: :   BIO-K+ is effective for preventing and reducing the severity of AAD
in patients receiving antibiotic therapy in a hospital setting.
K Ke ey y   w wo or rd ds s: :   lactobacillus, antibiotic associated diarrhea, probiotics, acidophilus. 
Introduction
Diarrhea  is  one  of  the  most  frequently  reported  adverse  events
associated with antibiotic treatment. Alterations in the balance and diversity
of the composition of the normal intestinal flora have been identified as
the two major factors involved in the pathogenesis of Antibiotic Associated
Diarrhea [1, 2]. The incidence of AAD varies widely with rates between 
10 to 30% and has been identified as the leading cause of diarrhea in
hospitalized patients [3]. The onset of AAD can occur as early as a few hours
after the first dose or as late as 2 months after discontinuation of antibiotic
C Co or rr re es sp po on nd di in ng g   a au ut th ho or r: :
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therapy [1]. Osmotic diarrhea is the most frequent
manifestation of AAD and is produced by alterations
in both carbohydrate fermentation and bile acid
metabolism caused by a decrease in anaerobic flora
[4, 5]. The magnitude of these changes is influenced
by  the  type  of  antibiotic  used  along  with  the
capability of the intestinal flora to resist to pathogen
colonization. In some occasions, the changes in the
makeup of the intestinal flora will lead to the
proliferation  of  pathogenic  organisms  such  as
Staphylococcus aureus, Candida spp., Klebsiella
oxytoca, and Clostridium difficile [5, 6]. Given that
the mechanism of action for AAD is based on an
acute disruption of the intestinal normal flora,
interventions that could counteract this effect that
are administered prior to or concurrently with the
antibiotic  treatment  would  be  efficacious  in
preventing or reducing the severity of AAD. 
The Food and Agricultural Organization of the
United Nations and World Health Organization have
defined probiotics as “live organisms which when
administered in adequate amounts confer a health
benefit on the host” [7].There is accumulating
evidence that probiotics are beneficial in preventing
and  shortening  the  duration  of  AAD  from  an
increasing  number  of  clinical  studies  [8-11].
Mechanisms  by  which  probiotics  exert  their
therapeutic effects include:
1) modulation of the epithelial cell barrier function,
2) antagonistic activity against pathogenic bacteria
either  by  inhibition  of  adherence  and
translocation or by production of antibacterial
substances,
3) modulation of intestinal cytokine production,
4) anti-inflammatory properties, and
5) improvement of gut permeability [12-14].
However, in a recent meta-analysis [15] only 13
(52%) out of 25 trials assessed reported a beneficial
effect  of  probiotics  in  preventing  AAD.  The
disagreement  in  the results  reported  in  these
studies may be due to differences in the patient
population, the type and dose of probiotics, the
class of antibiotics used, and the duration of the
treatment [15].
The  role  of  the  Lactobacillus  genus  on  the
reduction of AAD has been vastly studied. Hickson
and co-workers reported the efficacy of a probiotic
drink containing Lactobacillus casei, Lactobacillus
bulgaricus, and Streptococcus thermophilus in the
reduction of the incidence of AAD and C. difficile-
associated diarrhea (CDAD) in a population of 135
elderly hospital patients [9]. In a recent study, 
a probiotic milk drink containing Lactobacillus
rhamnosus GG, Lactobacillus acidophilus La-5 and
Bifidobacterium Bb-12 reduced the risk of AAD by
79% in hospitalized adult patients [10]. The strain
L. rhamnosus GG was also proven effective in the
prevention of AAD in a sample of 188 children
treated with oral antibiotics for common childhood
infections [16]. 
In assessing the potential benefits of probiotics
in AAD it should be noted that the effect is highly
strain specific and generalization of the results to
related strains is not valid [10, 17]. It is therefore
essential  that  individual  strains  are  assessed
independently  and  that  the  results  must  be
interpreted for the specific strain. 
BIO K+ CL1285® is a commercially available
probiotic with a patented formula containing the 
L. acidophilus CL1285® strain of human origin,
registered at the Pasteur Institute, and a L. casei
strain. In a randomized clinical trial the fermented
milk formula, formulation of BIO K+ CL1285®, was
shown to be efficacious in preventing AAD in
hospitalized patients [11]. However, this was a single
center study with a relatively small sample size.
There  is  consensus  among  experts  that  well
designed clinical trials with larger sample size are
required to adequately assess and demonstrate the
efficacy of probiotics in the management and
prevention of AAD [10, 15, 17, 18].
Based on the above discussion it is anticipated
that administration of BIO K+ CL1285® concurrently
with  an  antibiotic  would  minimize  the  desta-
bilization of the intestinal normal flora and be
efficacious in reducing AAD. The objective of the
present study was to assess the efficacy and safety
of BIO K+ CL1285® compared to placebo in reducing
the incidence and severity of AAD in patients
treated in a hospital setting.
Material and methods
S St tu ud dy y   d de es si ig gn n   a an nd d   t tr re ea at tm me en nt t
This was a multicenter double-blind, randomized,
placebo controlled, study that was conducted in eight
Canadian centers between March 2006 and October
2007. Patients were randomized at a 1 : 1 ratio to
receive BIO K+ or a placebo. The formulation of the
BIO K+ CL1285® lactobacilli fermented milk was 
a combination of 50 × 109 colony forming units of 
L. acidophilus CL1285® and L. casei (BIO K+ CL1285®,
BIO K+ International Inc., Canada). The duration of
treatment was between 29 and 40 days. The dosage
schedule was 49 g/day for the first 2 days, in order
to evaluate the tolerance of the patient to the
product, followed by a full dose of 98 g/day for the
remaining  treatment  period.  The  placebo  was
prepared  by  BIO  K+  International  and  was 
a lactoserum devoid of any microorganisms with
similar texture and flavor as to BIO K+. Both the BIO
K+ and placebo preparations were administered
within 24 h after the first dose of antibiotic and
continued  once  daily  within  ±  2  h  of  the
administration of the antibiotic treatment and for 
5 days following the termination of antibiotic regimen. 
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Diary cards were provided to patients to record
antibiotic and study product use along with the
presence of diarrhea during the treatment period.
Additional follow up assessments were conducted at
21 days after treatment termination. For the 21 day
follow up period patients were instructed to complete
the diary cards only when diarrhea occurred. 
Testing  for  CDAD  was  performed  at  the
discretion of the treating physician and according
to the protocol in place at the study centers. CDAD
was defined as an episode of diarrhea and positive
results for C. difficile Toxin A or B. Data for patients
discharged from the hospital before the end of the
study were obtained by a self administered diary
and standardized telephone interview. 
All statistical analyses were conducted on the
Intent to Treat (ITT) population that was comprised
of any patient that received at least one dose of
the  study  product,  a  minimum  of  three  days
antibiotic treatment and had at least one follow up
visit to allow ascertainment of the study outcomes. 
Potentially eligible patients signed an informed
consent form prior to the performance of any study
procedure. The study protocol was approved by the
internal review board of each institution and was
conducted according to the principles of Declaration
of Helsinki. 
S St tu ud dy y   p po op pu ul la at ti io on n
In order to be eligible for inclusion in the study
patients had to be 18 years or older, treated in an
emergency room or hospital ward for a minimum
of 12 h, and scheduled to receive antibiotic therapy
for a minimum of three days and a maximum of 
14 days. All patients were required to have received
no more than 24 h of antibiotic therapy before
being  enrolled  in  the  study.  Exclusion  criteria
included active diarrhea at enrollment, a history of
daily consumption of fermented milk and/or yogurt,
known lactose intolerance, pregnant/breastfeeding
women,  an  active  and  uncontrolled  intestinal
disease, history of an ileostomy, a jejunostomy or
a  colostomy,  an  immune-suppressive  state  or
condition, a diagnosis of C. difficile-associated
diarrhea within the previous three months, active
radiotherapy or chemotherapy, a recent (< 6 months)
or planned bone marrow graft or organ transplant,
prior  antibiotic  therapy  in  the  fourteen  days 
prior  to  study  initiation,  current  or  planned
administration  of  metronidazole  (alone  or  in
combination) or vancomycin monotherapy for the
treatment of an infection, and participation in
another clinical trial.
O Ou ut tc co om me e   m me ea as su ur re es s
The primary efficacy outcome measures were
the  severity  and  incidence  of  AAD  during  the
treatment period and the 21 day follow up. In
ascertaining the study outcome, a day of diarrhea
was defined as one or more episodes of unformed
or liquid stool in a 24 h period. Incidence of diarrhea
was defined as the proportion of patients with one
or more days with diarrhea over the total number
of patients in the ITT population. Severity was
assessed by duration defined as the total number
of days with diarrhea. Secondary efficacy outcome
measures included the incidence of CDAD. Safety
was  assessed  by  the  incidence  of  treatment-
emergent adverse events, which were reported
according to the MedDRA (version 10.1) dictionary
of terms. 
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Sample size calculations were established in
order to detect a 50% reduction in the incidence of
diarrhea in favor of the treatment group. Based on
available data in the literature and preliminary
results on BIO K+ a 20% incidence of diarrhea in
the placebo was anticipated. Therefore in order to
detect statistical significance with 80% power and
5% significance as well as a relative risk of 0.50, 
a total of 200 evaluable patients per group were to
be enrolled in the study. Allowing for 20% attrition,
a total of 500 patients were to be recruited.
Descriptive statistics including the mean and
standard deviation for continuous scale variables
and frequency distributions for categorical variables
were reported for all study variables by treatment
group. The between-group difference with respect
to the incidence of diarrhea was assessed for
statistical significance with the ˇ2 test. The relative
risk as estimated by the logistic regression based
odds ratio was used to assess the magnitude and
precision  of  the  difference.  The  statistical
significance of the between group difference with
respect to the duration of diarrhea was assessed
with the Student’s t-test for Independent samples.
Adjusted analyses were based on Multivariate
Binary Logistic regression for incidence of diarrhea
and General Linear Models for duration of diarrhea.
In the adjusted analyses potential confounding
variables that were included as covariates in the
multivariate models were age, gender, duration of
treatment, duration of antibiotic use, change in
antibiotic use, and history of AAD. These covariates
were selected a priori because of their potential
importance as risk factors and prognostic predictors
for diarrhea. The backward selection process based
on the Wald statistic with an α tolerance of 0.15
was used to select the final set of covariates
included in the multivariate models. 
Safety evaluation was conducted on all patients
receiving at least one dose of the study treatment
and was assessed by the number of events and the
number  of  patients  experiencing  at  least  one
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serious or non-serious treatment related adverse
event during the treatment period. Causal relation
of  the  adverse  event  to  the  study  drug  was
ascertained by the treating physician. 
All analyses were based on the Intent to Treat
population. No patients were excluded from the
analyses because of protocol violation or non-
compliance. There were no replacements of missing
values or imputations applied and all analyses were
conducted  on  observed  cases.  The  Statistical
Product and Service Solutions (SPSS version 12.0
for Windows) was used for all statistical analyses.
Results
P Pa at ti ie en nt t   d di is sp po os si it ti io on n   a an nd d   b ba as se el li in ne e   c ch ha ar ra ac ct te er ri is st ti ic cs s
Among the 472 randomized patients, 29 patients
were  excluded  from  the  ITT  analysis  due  to
antibiotic treatment duration of less than 3 days
and 6 patients were excluded because diarrhea
onset occurred before initiation of study treatment.
Therefore a total of 437 (92.6%) were included in
the ITT population (Figure 1). 
The  patient  demographics  and  baseline
characteristics were similar for the BIO K+ and
placebo groups (Table I). More than 50% of the
patients were hospitalized with a mean duration of
hospital stay of 8.8 and 7.1 for the BIO K+ and
placebo groups respectively. The most frequent type
of  antibiotic  received  during  the  study  was 
β-lactams, including cephalosporin and penicillin,
by 76.9% of the patients in the BIO K+ group and
78.3% of the patients in the placebo group. The
most frequent underlying condition for antibiotic
use was respiratory infections for 39.4% of the
patients in the BIO K+ group and 38.5% of the
patients in the placebo group. The mean (SD)
duration of antibiotic treatment was 9.8 (3.9) days
for the BIO K+ group and 9.7 (3.8) days for the
placebo group. The mean duration of treatment
with the study product was approximately 12.0 days
for both groups. 
E Ef ff fi ic ca ac cy y   o ou ut tc co om me es s
The mean (SD) duration of diarrhea was 0.67
(2.05) [95% CI: 0.39-0.94] days for the BIO K+ group
and 1.19 (3.20) [95% CI: 0.77-1.62] days for the
placebo group (p = 0.040) (Table II). The backward
selection procedure for the multivariate linear
regression  model  assessing  between  group
2 21 15 51 1   p pa at ti ie en nt ts s   e ev va al lu ua at te ed d   f fo or r   e el li ig gi ib bi il li it ty y
2 23 33 3: :   B BI IO O   K K+ +   C CL L1 12 28 85 5® ® g gr ro ou up p 2 23 39 9: :   p pl la ac ce eb bo o   g gr ro ou up p
2 21 16 6   i in nc cl lu ud de ed d   i in n   I IT TT T   a an na al ly ys si is s
1 17 7   e ex xc cl lu ud de ed d
14: ANTB treatment < 3 days
3: Diarrhea onset prior to
initiation
2 22 21 1   i in nc cl lu ud de ed d   i in n   I IT TT T   a an na al ly ys si is s
1 18 8   e ex xc cl lu ud de ed d
15: ANTB treatment < 3 days
3: Diarrhea onset prior to
initiation
1 16 67 79 9   p pa at ti ie en nt ts s   e ex xc cl lu ud de ed d* *
506: Antibiotic therapy 14 days prior
to study initiation
227: Monotherapy with vancomycin
or metronidazole (alone or in
combination)
176: Mental patient or language
barrier
172: No informed consent obtained
164: Patient unlikely to comply with
protocol
112: Screening failures
79: Diarrhea, lactose intolerance,
enterostomized patients,
underlying gastrointestinal
tract disease
68: Immune compromised state
(chemotherapy or radiotherapy
within the last year, use of
immunosuppressant
medication, transplant patient)
53: Antibiotics ≥ 24 h
47: Duration of antibiotic therapy 
< 3 days 
33: Regular probiotic intake
17: Doctor’s refusal
9: Did not meet entry
hospitalization requirement
7: Pregnant or breast-feeding
5: Diagnosis of Clostridium difficile
< 3 months
5: Use of illicit drugs and/or
alcohol abuse
4: Age < 18 years
3: Patient involved in another study
4 47 72 2   p pa at ti ie en nt ts s   r ra an nd do om mi iz ze ed d
F Fi ig gu ur re e   1 1. .   Patient disposition
*8 patients reported more than one reason for exclusion; ITT – intent to treat, ANTB – antibiotic
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T Tr re ea at tm me en nt t   g gr ro ou up p P P- -v va al lu ue e   
B BI IO O   K K+ +   C CL L1 12 28 85 5® ® P Pl la ac ce eb bo o
( (N N = =   2 21 16 6) ) ( (N N = =   2 22 21 1) )
A Ag ge e   [ [y ye ea ar rs s] ], ,   m me ea an n   ( (S SD D) ) 59.5 (18.1) 58.1 (19.1) 0.409
A Ag ge e   c ca at te eg go or ri ie es s   [ [y ye ea ar rs s] ], ,   N N ( (% %) )
G Ge en nd de er r, ,   N N ( (% %) ): :
• Male 117 (54.2) 107 (48.4)
0.251
• Female  99 (45.8) 114 (51.6)
D Di is st tr ri ib bu ut ti io on n   o of f   p pa at ti ie en nt ts s   p pe er r   h ho os sp pi it ta al l, ,   N N ( (% %) ): :
• Centre Hospitalier Régional de Trois Rivie `res 24 (11.1) 19 (8.6)
• St. Mary’s Hospital 11 (5.1) 12 (5.4)
• Hôpital Hôtel-Dieu de Saint-Jérôme 68 (31.5) 76 (34.4)
• Hamilton General Hospital 6 (2.8) 6 (2.7)
• Hôpital Laval 24 (11.1) 23 (10.4)
• Kingston General Hospital 34 (15.7) 39 (17.6)
• North York General Hospital 36 (16.7) 35 (15.8)
• Centre de Santé et de Services Sociaux de Chicoutimi 13 (6.0) 11 (5.0)
T Ty yp pe e   o of f   c ca ar re e, ,   N N ( (% %) ): :
• Hospitalized 118 (54.6) 130 (58.8)
0.386
• Out patients 98 (45.4) 91 (41.2)
H Ho os sp pi it ta al li iz za at ti io on n   d du ur ra at ti io on n   [ [d da ay ys s] ], ,   m me ea an n   ( (S SD D) ) 8.8 (15.1) 7.1 (6.4) 0.302
H Hi is st to or ry y   o of f   C CD DA AD D   a an nd d/ /o or r   A AA AD D, ,   N N ( (% %) ) 3 (1.4) 5 (2.3) 0.724
C Co on nc co om mi it ta an nt t   m me ed di ic ca at ti io on ns s   i in n   t th he e   l la as st t   1 15 5   d da ay ys s, ,   N N ( (% %) ): :
• Laxative 20 (9.3) 19 (8.6) 0.868
• Anti-inflammatory  54 (25.0) 50 (22.6) 0.576
• Antacid 14 (6.5) 21 (9.5) 0.291
• Aspirin 61 (28.2) 58 (26.2) 0.668
• Proton-pump inhibitor 51 (23.6) 62 (28.1) 0.326
• Opiate 28 (13.0) 29 (13.1) 0.999
D Du ur ra at ti io on n   o of f   a an nt ti ib bi io ot ti ic c   t th he er ra ap py y   [ [d da ay ys s] ], ,   m me ea an n   ( (S SD D) )    9.76 (3.85) 9.65 (3.76) 0.768
D Du ur ra at ti io on n   o of f   t tr re ea at tm me en nt t   [ [d da ay ys s] ], ,   m me ea an n   ( (S SD D) ) 12.37 (5.21) 11.99 (4.93) 0.429
A An nt ti ib bi io ot ti ic cs s   r re ec ce ei iv ve ed d   d du ur ri in ng g   s st tu ud dy y§ §, ,   N N ( (% %) ): :
• β-Lactams 166 (76.9) 173 (78.3) 0.732
• Quinolones 68 (31.5) 70 (31.7) 0.999
• Macrolides 51 (23.6) 51 (23.1) 0.910
• Clindamycin 18 (8.3) 14 (6.3) 0.466
• Other:
- Metronidazole 1 (0.5) 0 (0.0) 0.494
- Septra 3 (1.4) 0 (0.0) 0.120
- Tetracycline 11 (5.1) 9 (4.1) 0.653
- Tobramycine 1 (0.5) 1 (0.5) 0.999
- Vancomycin 0 (0.0) 1 (0.5) 0.999
- Linezolide 1 (0.5) 0 (0.0) 0.494
U Un nd de er rl ly yi in ng g   i in nf fe ec ct ti io on ns s   f fo or r   a an nt ti ib bi io ot ti ic c   t tr re ea at tm me en nt t, ,   N N ( (% %) ): :
• Respiratory 85 (39.4) 85 (38.5) 0.922
• Skin 49 (22.7) 50 (22.6) 0.999
• Urogenital tract 23 (10.6) 36 (16.3) 0.094
• Other 65 (30.1) 52 (23.5) 0.131
CDAD – clostridium difficile-associated diarrhea; §there were 163 patients who received more than 1 type of antibiotic
T Ta ab bl le e   I I. .   Demographics and baseline characteristics
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difference with respect to duration of diarrhea,
retained in the model the following variables:
treatment group, duration of antibiotic therapy,
patient’s age and duration of study treatment while
gender, change in antibiotic treatment and history
of AAD were not retained. The final linear regression
model showed a significant treatment effect with
a reduction on the adjusted mean number of days
with diarrhea in the BIO K+ group vs. the placebo
group of 51.5% (b[SE] = 0.515 [0.256]; 95% CI [0.012-
1.018]).The adjusted least square mean estimates
based on this multivariate linear regression for the
number of days with diarrhea were similar to the
unadjusted estimates and the between group
adjusted difference remained statistically significant
(p = 0.045). 
The incidence of diarrhea was 21.8% in the BIO K+
group compared to 29.4% in the placebo group. This
difference  approached  statistical  significance 
(odds  ratio  [95%  CI]  =  0.667  [0.433-1.030], 
p =  0.067).  However,  the  study  sample  was
underpowered, with only 40% power, to detect as
statistically significant this difference. The final
multivariate logistic regression model assessing the
between group difference with respect to the
incidence of new onset AAD retained the same
covariates  as  the  linear  regression  model,
specifically treatment group, duration of study
treatment,  duration  of  antibiotic  therapy,  and
patient’s age. The results of this analysis showed
a statistically significant adjusted odds ratio of
diarrhea for the BIO K+ group vs. the placebo group
of 0.627 (95% CI [0.405-0.971], p = 0.037). 
There were 12.5% of the patients in the BIO K+
group and 19.0% in the placebo group with diarrhea
≥ 2 days (p = 0.062). The proportion of patients with
≥ 3 days diarrhea was 7.9% in the BIO K+ group and
13.6% patients in the placebo group (p = 0.054).
These differences approached statistical significance
with the study being underpowered, 40 and 42%
respectively, to detect these effects as statistically
significant The adjusted odds ratios of BIO K+ vs.
placebo were 0.554 (95% CI: 0.326-0.940, p = 0.029)
for diarrhea duration ≥ 2 days and 0.504 (95% CI:
0.269-0.944, p = 0.032) for diarrhea ≥ 3 days. 
There were 16 patients in the BIO K+ group and
30 in the placebo group that underwent CDAD
testing. Of these, 1 (6.2%) patient in the BIO K+
group and 4 (13.3%) in the placebo group were
positive for the C. difficile toxins (odds ratio = 0.433,
p = 0.645). The incidence of bloating was 21.8% in
the BIO K+ group vs. 19.9% in the placebo group. For
painful cramps the incidence was 14.8% in the BIO K+
and 15.8% in the placebo group while that for bloody
stools was 1.9 vs. 4.1% respectively. None of these
differences were statistically significant.
S Sa af fe et ty y
One or more treatment-emergent non serious
adverse event (NSAE) was reported by 72 (33.3%)
patients in the BIO K+ group and 76 (34.4%) patients
in the placebo group. There was no statistically
significant difference between the two study groups
with respect to the incidence of treatment-emergent
NSAEs (Table III). The most frequently reported non
serious adverse events were constipation, flatulence
and nausea. A total of 38 serious adverse events were
reported; 15 in the BIO K+ group and 23 in the
placebo group, during the course of the study. None
of the serious adverse events were related to the
treatment product. There were eight deaths reported
during the study, four in the placebo group and three
in the BIO K+ group. None of the deaths were
causally related to the study product. 
Discussion
The results of this randomized, double-blind,
placebo-controlled  trial  have  shown  that  the
T Tr re ea at tm me en nt t   g gr ro ou up p O Od dd ds s   r ra at ti io o P P- -v va al lu ue e   
B BI IO O   K K+ +   C CL L1 12 28 85 5® ® P Pl la ac ce eb bo o
( (9 95 5% %   C CI I) )
( (N N = =   2 21 16 6) ) ( (N N = =   2 22 21 1) )
U Un na ad dj ju us st te ed d   a an na al ly ys si is s
Severity: 
mean (SD) number of days with diarrhea 0.67 (2.05) 1.19 (3.20) NA 0.040
Incidence: 21.8 29.4 0.667 0.067
(%) of patients with ≥ 1 day of diarrhea (0.433-1.030)
A Ad dj ju us st te ed d   a an na al ly ys si is s* *
Severity:  0.67 (0.37) 1.19 (0.42) NA 0.045
mean (SE) number of days with diarrhea§
Incidence: 21.8 31.7 0.627 0.037
(%) of patients with ≥ 1 day of diarrhea – (0.405-0.971)
*Adjusted for age, duration of treatment with study product, duration of treatment with antibiotics, §Least Square Mean Estimates based on
linear regression analysis,  –based on Multi-Variate Logistic Regression Analysis, SD – standard deviation, SE – standard error
T Ta ab bl le e   I II I. . Efficacy outcomes 
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lactobacilli-fermented milk product BIO K+ CL1285®
is effective in reducing the severity and incidence
of  AAD  in  patients  treated  with  antibiotics in 
a hospital setting. 
The duration of diarrhea used as a measure of
severity of AAD, was 1.19 days in the placebo group
and  0.67  days  in  the  BIO  K+  group.  This  is 
a statistically and clinically significant unadjusted
reduction  of  43.7%  in  the  mean  duration  of
diarrhea. After adjusting for baseline prognostic
variables the results show that, on the average,
diarrhea will be reduced by 51.5% in patients
treated with BIO K+ compared to those treated with
placebo. This reduction in the duration of diarrhea,
which is both clinically important and statistically
significant, has major implications for patient’s
quality of life as well as direct and indirect health
care costs related to the management of AAD. 
The results of this study showed a 33% unadjusted
reduction in the risk of diarrhea (incidence) in the
patients treated with BIO K+ compared to placebo.
Although this treatment effect is clinically important,
the study was not sufficiently powered to detect this
effect size as statistically significant. The low power
was due to higher (29.4%) than the expected 20%
incidence of diarrhea in the placebo group. This is 
a possible weakness of the current study, which is
related to the assumptions used for sample size
calculations. The multivariate logistic regression
analyses controlled for the effect of the covariates,
thus reducing within group variance and improving
the power of the study. These results showed that
after adjusting for the effect of potential confounders,
the treatment with BIO K+ resulted in a statistically
significant 37.3% reduction in the risk of AAD. While
the type of concomitant medication used may be
associated with increased risk for diarrhea; the two
groups were very well matched with respect to this
parameter and therefore there is no concern for
confounding on the treatment effect.
The results of the current study are comparable
with others that have reported the effectiveness of
probiotics in reducing the incidence of AAD [9-11,
16, 17, 19-21]. However, the majority of these studies
have been conducted on smaller number of patients.
Conversely, the current study was conducted in
several centers across Canada and in a larger and
more diverse patient sample that is representative
of  the  target  population.  The  pathogenesis  of
antibiotic related diarrhea is based on the disruption
of the intestinal normal flora. Probiotics including
lactobacilli are efficacious in restoring normal flora
and thus preventing or reducing the duration of
diarrhea. A similar mechanism of action for the
benefits of probiotics has been noted for Crohn’s
disease [22], irritable bowel syndrome [23], ulcerative
colitis [24], and patients undergoing ileal pouch anal
anastomosis [25].
The major strength of the present study is
inherited in the double blind, placebo controlled
design. Given the merit of double blind, controlled
trial,  the  results  of  the  current  study  provide
evidence that the BIO K+ CL1285® lactobacilli-
fermented probiotic is effective in the prevention
of antibiotic associated diarrhea. These results have
important  implications  for  the  general  target
population treated with antibiotics in a hospital
setting and show that treatment with BIO K+ CL1285®
will reduce the duration of diarrhea by approxima-
tely one half and the risk for diarrhea by more than
one third. This will result in significantly improved
patient quality of life and health care cost savings
by  reduced  hospitalizations  and  health  care
resource utilization.
In recent years there has been an increase in the
incidence of C. difficile infection in hospital settings,
with the elderly hospitalized patients being at
increased risk. In fact between 10-20% of C. difficile
cases are observed in the elderly patients [26]. In
the current study, despite the low overall incidence
of C. difficile, a lower rate was observed in the
lactobacilli compared to the placebo group. It should
be noted, however, that testing for C. difficile was
not conducted on all patients and that testing was
dependent on the decision of the treating physician
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Gastrointestinal adverse events:
• Constipation 12 (5.6) 8 (3.6)
• Flatulence 7 (3.2) 13 (5.9)
• Nausea 7 (3.2) 5 (2.3)
• Vomiting 5 (2.4) 0 (0.0)
• Dyspepsia 0 (0.0) 2 (0.9)
• Dysphagia 1 (0.5) 0 (0.0)
• Eructation 0 (0.0) 1 (0.5)
• Fecal incontinence 1 (0.5) 0 (0.0)
• Gastro esophageal  1 (0.5) 0 (0.0)
• reflux disease
• Glossitis 0 (0.0) 1 (0.5)
• Reflux gastritis 1 (0.5) 0 (0.0)
Other adverse events:
• Vulvovaginal mycotic 0 (0.0) 2 (0.9)
infection
• Muscle spasms 0 (0.0) 2 (0.9)
• Hyperthermia 0 (0.0) 1 (0.5)
• Pyrexia 0 (0.0) 1 (0.5)
• Arthralgia 1 (0.5) 0 (0.0)
• Headache 1 (0.5) 0 (0.0)
• Dyspnea 0 (0.0) 1 (0.5)
• Presence of at least one  72 (33.3) 76 (34.4)
treatment-emergent non 
serious adverse event
T Ta ab bl le e   I II II I. .   Treatment-emergent non serious adverse
events 
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and hospital protocols. Further research on the
assessment  of  the  efficacy  of  BIO  K+  in  the
prevention of CDAD is required as this nosocomial
infection  remains  an  important  health  issue
worldwide. 
Despite the high proportion of patients reporting
at least one adverse event in each group, the
majority (80%) of the events were mild in severity
and the incidence was similar for the placebo and
treatment groups. These results show that BIO K+
was overall safe and well tolerated. 
In conclusion, this study demonstrates that
probiotic prophylaxis with BIO K+ CL1285® is safe
and  efficacious  in  reducing  the  incidence  and
duration of antibiotic associated diarrhea in patients
receiving antibiotic treatment in a hospital setting. 
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